Modification of breast cancer milieu with chemotherapy plus dendritic cell vaccine: an approach to select best therapeutic strategies

Background: The addition of dendritic cell vaccines (DCV) to NAC could induce immune responses in those patients with residual disease (RD) by transforming the tumor microenvironment. Methods: Core diagnostic biopsies and surgical specimens from 80 patients (38 in the vaccinated group plus NAC (VG)...

Descripción completa

Detalles Bibliográficos
Autores: Mejías-Sosa, L.D. (Luis D.)|||/items/8fc6fe84-3f9d-4edf-8ed6-2f447904b811, López-Janeiro, Á. (Álvaro)|||/items/1eabe5f2-a198-4d7c-9b57-81bcd0aa2201, Córdoba-Iturriagagoitia, A. (Alicia)|||/items/7167cac2-91c1-4eb7-9555-67a0ae389e05, Sala-Elarre, P. (Pablo)|||/items/a91400e6-6375-4f58-a68e-9adf0eb4d678, Pérez-Solans, B. (Belén)|||/items/7ed12961-3ac5-46b8-a41d-6403d2afd675, Hato-Álvaro, L. (Laura)|||/items/7ef1f289-4652-46e5-b0ef-65d7d1e42559, Inoges-Sancho, S.I. (Susana Inmaculada)|||/items/3e5dc866-6d34-4005-b3bc-405b2bdf9992, Lopez-Diaz-de-Cerio, A. (Ascensión)|||/items/29ab6acb-fcbb-43ff-b4c1-e2dc95e22bcb, Guillen-Grima, F. (Francisco)|||/items/44df30ec-7465-4d78-9f76-c647e8fb50da, Espinós-Jiménez, J. (Jaime)|||/items/6e9f39c5-179b-4206-8076-1fd35594b80f, Cruz, S. (S.) de la|||/items/ae1ad743-3e35-4c1e-903c-f91176a9bf40, Lozano-Escario, M.D. (María Dolores)|||/items/af4b6129-2049-4083-8d70-40d37f172598, Idoate, M.A. (Miguel Ángel)|||/items/7b905180-f34f-450d-934f-8bf7652f84d3, Santisteban-Eslava, M. (Marta)|||/items/563d2cef-8a22-4110-97f4-8e16eac15419
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/65919
Acceso en línea:https://hdl.handle.net/10171/65919
Access Level:acceso abierto
Palabra clave:Breast cancer
Dendritic cell vaccine
TILs
Neoadjuvant chemotherapy
CD8 and triple negative
Descripción
Sumario:Background: The addition of dendritic cell vaccines (DCV) to NAC could induce immune responses in those patients with residual disease (RD) by transforming the tumor microenvironment. Methods: Core diagnostic biopsies and surgical specimens from 80 patients (38 in the vaccinated group plus NAC (VG) and 42 in the control group (CG, treated only with NAC) were selected. We quantify TILs (CD8, CD4 and CD45RO) using immunohistochemistry and the automated cellular imaging system (ACIS III) in paired samples. Results: A CD8 rise in TNBC samples was observed after NAC plus DCV, changing from 4.48% in the biopsy to 6.70% in the surgical specimen, not reaching statistically significant differences (p = 0.11). This enrichment was seen in up to 67% of TNBC patients in the experimental arm as compared with the CG (20%). An association between CD8 TILs before NAC (4% cut-off point) and pathological complete response in the VG was found in the univariate and multivariate analysis (OR = 1.41, IC95% 1.05-1.90; p = 0.02, and OR = 2.0, IC95% 1.05-3.9; p = 0.03, respectively). Conclusion: Our findings suggest that patients with TNBC could benefit from the stimulation of the antitumor immune system by using DCV together with NAC.

Similares en LA Referencia